# APOL6

## Overview
APOL6, or apolipoprotein L6, is a gene that encodes a protein belonging to the apolipoprotein L family, which is involved in lipid metabolism and storage. The protein, apolipoprotein L6, is characterized by a unique structure that includes a cysteine-rich transmembrane domain, an apolipoprotein-like domain, and a hydrophobic domain, but notably lacks a N-terminal signal sequence. This structural configuration allows apolipoprotein L6 to associate with lipid droplets in adipocytes, where it plays a critical role in inhibiting lipolysis by interacting with perilipin1 (Plin1). The protein's function extends to potential roles in apoptosis and mitochondrial targeting, drawing parallels with the Bcl-2 family of proteins. APOL6's expression is modulated by nutritional status, and its dysregulation has been implicated in various clinical conditions, including cancer and metabolic disorders, highlighting its significance in both physiological and pathological contexts (Wang2022A; Pant2021Apolipoproteins; Wang2024ApoL6).

## Structure
APOL6, or apolipoprotein L6, is characterized by a unique molecular structure within the apolipoprotein L family. It features a distinct C-terminal extension that includes a cysteine-rich predicted transmembrane domain. This domain is similar to those found in antimicrobial peptides and is hypothesized to disrupt lipid membrane integrity through a mechanism known as the carpet model (Pant2021Apolipoproteins). The C-terminal domain is crucial for its function, as it is responsible for binding to phosphatidylinositol (4,5)-bisphosphate (PI(4,5)P2) on lipid droplets, with positive charges at this domain being essential for interaction (Wang2024ApoL6).

APOL6 also contains an apolipoprotein-like domain in the middle and a hydrophobic domain near the N-terminus, but it lacks a N-terminal signal sequence (Wang2024ApoL6). The protein is associated with lipid droplets in adipocytes and is involved in inhibiting lipolysis by interacting with perilipin1 (Plin1) (Wang2024ApoL6). The C-terminal region may also act as a mitochondrial targeting sequence, similar to proteins in the Bcl-2 family, suggesting a role in apoptosis (Pant2021Apolipoproteins). APOL6's structure and function are distinct from other APOL proteins, highlighting its unique evolutionary path (Pant2021Apolipoproteins).

## Function
Apolipoprotein L6 (APOL6) is a protein associated with lipid droplets in adipose tissue, playing a crucial role in lipid metabolism and storage. In healthy human cells, APOL6 is primarily involved in the regulation of lipolysis, the process by which stored triacylglycerol (TAG) in lipid droplets is broken down into fatty acids. APOL6 inhibits lipolysis by interacting with Perilipin 1 (Plin1), a protein that regulates lipid metabolism, thereby preventing the binding of hormone-sensitive lipase (HSL) to Plin1. This interaction is independent of the phosphorylation status of Plin1 and is crucial for inhibiting lipolysis (Wang2022A).

The C-terminal domain of APOL6 is essential for its binding to Plin1 and its association with lipid droplets. Overexpression of APOL6 leads to larger lipid droplets and increased TAG content, while knockdown results in smaller droplets with lower TAG content (Wang2022A; Wang2024ApoL6). APOL6 expression is modulated by nutritional status, increasing upon feeding and decreasing during fasting, which aligns with its role in energy metabolism and adipose tissue function (Wang2022A).

## Clinical Significance
Alterations in the expression of the APOL6 gene have been implicated in several diseases and conditions. In cancer, APOL6 overexpression can lead to mitochondria-mediated apoptosis, which is associated with the release of cytochrome-c and Smac/DIABLO from mitochondria in human cancer cells. This suggests a potential role in cancer cell death and highlights its clinical significance in oncology (Pant2021Apolipoproteins). 

In metabolic disorders, APOL6 is involved in lipid metabolism and its expression affects lipolysis. Overexpression of APOL6 in transgenic mice leads to reduced lipolysis, increased adiposity, and insulin resistance, suggesting a role in obesity and related metabolic conditions. Conversely, APOL6 knockout mice show protection from diet-induced obesity and improved glucose tolerance, indicating that APOL6 may influence insulin sensitivity and energy metabolism (Wang2024ApoL6).

In the context of immunotherapy for bladder cancer, APOL6 has been identified as a potential biomarker for predicting treatment efficacy. Its expression is associated with increased immune cell infiltration and a more inflamed tumor microenvironment, which may enhance the response to immune checkpoint inhibitors (Fan2024APOL6). APOL6's involvement in ferroptosis, a form of programmed cell death, further underscores its potential as a therapeutic target in cancer treatment (Fan2024APOL6).

## Interactions
Apolipoprotein L6 (APOL6) is known to interact with several proteins, particularly in the context of lipid metabolism and lipolysis inhibition. APOL6 directly interacts with Perilipin 1 (Plin1), a lipid droplet-associated protein, through its C-terminal domain. This interaction is crucial for inhibiting lipolysis, as it prevents the binding of hormone-sensitive lipase (HSL) to Plin1, thereby disrupting the Plin1-HSL interaction necessary for lipolysis (Wang2022A; Wang2024ApoL6). The interaction between APOL6 and Plin1 occurs regardless of the phosphorylation status of Plin1, which is typically required for Plin1-HSL interaction (Wang2024ApoL6).

APOL6 does not directly interact with HSL or adipose triglyceride lipase (ATGL), although it may form part of a larger lipolytic complex on the lipid droplet surface (Wang2024ApoL6). The interaction with Plin1 has been confirmed through various experimental techniques, including co-immunoprecipitation, immunofluorescence, and GST pull-down assays (Wang2024ApoL6). These findings highlight the role of APOL6 in regulating lipid metabolism by modulating protein interactions at the lipid droplet surface.


## References


1. (Wang2022A) A new LD protein, ApoL6 disrupts the Perilipin 1-HSL interaction to inhibit lipolysis. This article has 1 citations.

[2. (Fan2024APOL6) Zhiwei Fan, Yiting Liu, Xuehai Wang, Yuting Xu, Ruiyao Huang, Weijian Shi, Yi Qu, Jialing Ruan, Chu Zhou, Xinyuan Zhao, and Lei Liu. Apol6 predicts immunotherapy efficacy of bladder cancer by ferroptosis. BMC Cancer, August 2024. URL: http://dx.doi.org/10.1186/s12885-024-12820-7, doi:10.1186/s12885-024-12820-7. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12885-024-12820-7)

[3. (Pant2021Apolipoproteins) Jyoti Pant, Joseph A. Giovinazzo, Lilit S. Tuka, Darwin Pe√±a, Jayne Raper, and Russell Thomson. Apolipoproteins l1-6 share key cation channel-regulating residues but have different membrane insertion and ion conductance properties. Journal of Biological Chemistry, 297(2):100951, August 2021. URL: http://dx.doi.org/10.1016/j.jbc.2021.100951, doi:10.1016/j.jbc.2021.100951. This article has 9 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.jbc.2021.100951)

[4. (Wang2024ApoL6) Yuhui Wang, Hai P. Nguyen, Pengya Xue, Ying Xie, Danielle Yi, Frances Lin, Jennie Dinh, Jose A. Viscarra, Nnejiuwa U. Ibe, Robin E. Duncan, and Hei S. Sul. Apol6 associates with lipid droplets and disrupts perilipin1-hsl interaction to inhibit lipolysis. Nature Communications, January 2024. URL: http://dx.doi.org/10.1038/s41467-023-44559-3, doi:10.1038/s41467-023-44559-3. This article has 3 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-023-44559-3)